FDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
Ireland's GH Research Q2 net loss widens on higher R&D costs
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Street View: Psychedelic sector gains after report Lilly nears AtaiBeckley acquisition
May Offer Up To $400 Million In Securities - SEC Filing
Enters At-The-Market Equity Offering Sales Agreement With Stifel - SEC Filing
Ireland's GH Research Q1 net loss widens on higher expenses
U.S. STOCKS ON THE MOVE-Seagate, GE Healthcare, Bloom Energy
U.S. STOCKS ON THE MOVE-ICON, Old Dominion, Energy companies
Psychedelic drug firm GH Research eases after $117.5 mln equity raise
Brief: Gh Research Announces Pricing Of $117.5 Million Underwritten Offering
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
Psychedelic drug developers rise after Trump signals regulatory support
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Psychedelic drug developers rally as Trump orders FDA to expedite reviews (updated)
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Psychedelic drug developers rise after Trump signals regulatory support
U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group